Pancreatic Cancer Research

ResearcherCedars-Sinai Medical CenterNo recent work listed

Ido Wolf

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9319-7612; OpenAlex author ID A5083392542. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 3 papers · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper

Papers 11

  1. Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option? Co-author DOI 10.3390/cancers15113049↗
  2. Genomic alterations drive metastases formation in pancreatic ductal adenocarcinoma cancer: deciphering the role of CDKN2A and CDKN2B in mediating liver tropism. Co-author DOI 10.1038/s41388-022-02184-2↗
  3. A Transgenic Model Reveals the Role of Klotho in Pancreatic Cancer Development and Paves the Way for New Klotho-Based Therapy. Co-author DOI 10.3390/cancers13246297↗
  4. Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08469-8↗
  5. Protective Desmoplasia in Pancreatic Adenocarcinoma: High Vitamin D Receptor Expression and Collagen Content. Co-author DOI 10.21873/anticanres.14667↗
  6. Desmoplasia in Lymph Node Metastasis of Pancreatic Adenocarcinoma Reveals Activation of Cancer-Associated Fibroblasts Pattern and T-helper 2 Immune Cell Infilt… Co-author DOI 10.1097/mpa.0000000000001261↗
  7. New somatostatin-drug conjugates for effective targeting pancreatic cancer. Co-author DOI 10.1016/j.bmc.2018.06.032↗
  8. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. Co-author DOI 10.1016/j.ejso.2018.07.057↗
  9. T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal Adenocarcinoma: A Marker For Prolonged Survival. Co-author DOI 10.1245/s10434-017-6237-0↗
  10. Number of evaluated lymph nodes and positive lymph nodes, lymph node ratio, and log odds evaluation in early-stage pancreatic ductal adenocarcinoma: numerology… Co-author DOI 10.1186/s12957-016-0983-5↗
  11. KL1 internal repeat mediates klotho tumor suppressor activities and inhibits bFGF and IGF-I signaling in pancreatic cancer. Last author DOI 10.1158/1078-0432.ccr-10-2749↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guy Lahat · 7 shared papers, 2016–2023 · strength 0.70
  2. Joseph M. Klausner · 7 shared papers, 2016–2023 · strength 0.70
  3. Nir Lubezky · 4 shared papers, 2016–2023 · strength 0.40
  4. Eran Nizri‏ · 4 shared papers, 2016–2020 · strength 0.35
  5. Tamar Rubinek · 4 shared papers, 2011–2022 · strength 0.35
  6. Alex Barenboim · 3 shared papers, 2018–2023 · strength 0.35
  7. Ido Nachmany · 3 shared papers, 2016–2020 · strength 0.23
  8. Yossi Maman · 1 shared paper, 2023 · strength 0.18
  9. Shani Journo · 1 shared paper, 2022 · strength 0.15
  10. Ethan S. Sokol · 1 shared paper, 2022 · strength 0.15
  11. Adi Vaknine Bahat · 1 shared paper, 2020 · strength 0.11
  12. Tammi Arbel Rubinstein · 1 shared paper, 2021 · strength 0.11
  13. Talia Golan · 1 shared paper, 2020 · strength 0.10
  14. Elena Ragozin · 1 shared paper, 2018 · strength 0.07
  15. Gary Gellerman · 1 shared paper, 2018 · strength 0.07
  16. Lilach Abramovitz · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.